Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.43 |
| ▸ | RXRB | P28702 | 8/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 7/20 | 0.43 |
| ▸ | RXRG | P48443 | 7/20 | 0.41 |
| ▸ | RARB | P10826 | 4/20 | 0.41 |
| ▸ | RARA | P10276 | 3/20 | 0.41 |
| ▸ | RARG | P13631 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794870 | 1.00 | RXRA (0.43) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL9501274 | 0.85 | RXRA (0.44) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL9498190 | 0.82 | RXRA (0.41) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL9876435 | 0.74 | CHRNA1 (0.45) | — | |
| SCHEMBL10839765 | 0.72 | ESR2 (0.41) | — | |
| SCHEMBL7520074 | 0.72 | RXRA (0.54) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL5156026 | 0.72 | CHRNB2 (0.40) | — | |
| SCHEMBL8340501 | 0.70 | RXRA (0.52) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL6293972 | 0.69 | HCRTR1 (0.32) | — | |
| SCHEMBL18857047 | 0.68 | USP2 (0.47) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4446001-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-10-16 | — | — | EP | claimed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | claimed |
| US-20240173230-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2024-05-30 | — | — | US | claimed |
| US-20230151305-A1 | FRAGRANCE COMPOSITION | SA, GIVAUDAN (CH) | 2023-05-18 | — | — | US | claimed |
| EP-4146778-A1 | FRAGRANCE COMPOSITION | Givaudan SA (CH) | 2023-03-15 | — | — | EP | claimed |
| CN-115551986-A | Fragrance composition | 奇华顿股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| US-11364184-B2 | Perfume compositions | GIVAUDAN SA (CH) | 2022-06-21 | — | — | US | claimed |
| EP-3295925-B2 | COMPOSITION FOR THE PERMANENT DEFORMATION OF HAIR HAVING REDUCED ODOUR | NOXELL CORP (US) | 2022-05-18 | — | — | EP | claimed |
| US-11332693-B2 | Organic compounds | GIVAUDAN SA (CH) | 2022-05-17 | — | — | US | claimed |
| WO-2016049394-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049396-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | claimed |
| EP-1737937-B1 | PERFUME COMPOSITIONS | GIVAUDAN NEDERLAND SERVICES BV (NL) | 2013-06-12 | — | — | EP | claimed |
| US-7781392-B2 | Perfume compositions | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2010-08-24 | — | — | US | claimed |
| US-20070287659-A1 | Perfume Compositions | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2007-12-13 | — | — | US | claimed |
| WO-1998056337-A1 | MALODOR REDUCING COMPOSITION CONTAINING AMBER AND MUSK MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-17 | — | — | WO | claimed |
| EP-0379981-B1 | ACETALES OF OXO-TETRALINES AND OF OXO-INDANES | L. GIVAUDAN & CIE Société Anonyme (CH) | 1993-04-07 | — | — | EP | claimed |
| US-5084440-A | Deodorizing compounds | GIVAUDAN CORPORATION (US) | 1992-01-28 | — | — | US | claimed |
| EP-0379981-A1 | Acetales of oxo-tetralines and of oxo-indanes | L. GIVAUDAN & CIE Société Anonyme (CH) | 1990-08-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | RXRA 1508/4885RXRB 1327/4885CYP26A1 331/4885 |
| US-20240173230-A1 | FRAGRANCE COMPOSITION | FABP2, FABP5, FAAH2 | RXRA 251/4885RXRB 288/4885CYP26A1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.